City of Hope researchers reported in Nature Medicine that PANXEON, an AI-enabled liquid biopsy, detected stage 1 and 2 pancreatic cancer about 87% of the time across nearly 1,800 patients from the U.S., Europe and Asia. The blood test also identified high-grade dysplasia, a precancerous pancreatic lesion, more than 64% of the time, with false-positive rates of 3% in low-risk groups and 16% in high-risk groups.

Why It Matters To Oncology

• PANXEON combines three biomarkers — circulating microRNAs, exosomal microRNAs and CA19-9 — into a single risk score, aiming to improve early detection in a cancer typically diagnosed late.

• For clinicians, the potential value is triage: flagging patients with pancreatic cysts, chronic pancreatitis, inherited risk or family history for imaging and closer surveillance rather than replacing standard diagnostics.

• The ability to detect high-grade dysplasia may be especially relevant to interception strategies and earlier intervention before malignant neoplasm becomes invasive pancreatic ductal adenocarcinoma.

The Financials

• Biocartis recently signed a deal with City of Hope that gives it an option to acquire rights to PANXEON, pointing to possible commercial development if the assay is validated further.

• The study lands weeks after the FDA approved Revolution Medicines' RAS inhibitor Rasonque (daraxonrasib) for metastatic pancreatic ductal adenocarcinoma, underscoring renewed commercial interest across the pancreatic cancer continuum.

What They're Saying

• Senior author Ajay Goel said combining multiple biological signals offers “a clearer picture of what may be happening in the pancreas,” versus single biomarkers that capture only part of the disease biology.

• Investigators emphasized the test is not meant to replace imaging or other diagnostic workups, but to help identify which high-risk patients should undergo further evaluation.

What's Next

• Key questions for oncology and drug discovery audiences are prospective validation, performance in real-world screening workflows and whether use of the assay changes referral patterns, stage at diagnosis or outcomes.

• Further development will likely focus on refining use in defined high-risk populations and integrating the score with imaging, cyst surveillance and interventional decision-making.